By Jake King
Against a backdrop of growing opioid abuse in the U.S., Endo Health Solutions (NASDAQ:ENDP - News) announced another step Monday night in its efforts to curb abuse of its older, first generation pain management drug, Opana ER, and solidify market dominance of its new abuse-resistant formulation, launched in mid-2012. The companyaddeda supplement to its existing Citizen Petition (CP) to the FDA, including the results of a year-long study that, according to the company, demonstrate, "abuse of the reformulated Opana ER was reduced by 59 percent, based on the total number of prescriptions dispensed, versus the rate observed for the non-tamper-resistant formulation of Opana ER, which is no longer being manufactured by the company."Continue reading.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us onTwitteror visit us athttp://www.propthink.com.
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available athttp://www.propthink.com/disclaimer.